| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 236 | 2023 | 312 | 38.120 |
Why?
|
| Neoplastic Cells, Circulating | 104 | 2023 | 105 | 19.170 |
Why?
|
| Female | 325 | 2023 | 2147 | 11.460 |
Why?
|
| Biomarkers, Tumor | 83 | 2023 | 148 | 10.760 |
Why?
|
| Humans | 349 | 2023 | 4119 | 9.710 |
Why?
|
| Bone Marrow | 35 | 2021 | 58 | 7.030 |
Why?
|
| Receptor, ErbB-2 | 54 | 2023 | 61 | 6.410 |
Why?
|
| Ovarian Neoplasms | 32 | 2022 | 52 | 6.140 |
Why?
|
| Middle Aged | 139 | 2023 | 843 | 5.820 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 43 | 2023 | 68 | 5.700 |
Why?
|
| Adult | 135 | 2021 | 944 | 4.900 |
Why?
|
| Neoplasm Recurrence, Local | 29 | 2022 | 48 | 4.670 |
Why?
|
| Prognosis | 92 | 2023 | 196 | 4.630 |
Why?
|
| Aged | 102 | 2021 | 580 | 4.250 |
Why?
|
| Receptors, Progesterone | 38 | 2020 | 42 | 3.700 |
Why?
|
| Antineoplastic Agents | 23 | 2020 | 77 | 3.130 |
Why?
|
| Neoplasm Staging | 55 | 2021 | 66 | 2.870 |
Why?
|
| Neoplasm Metastasis | 36 | 2021 | 47 | 2.750 |
Why?
|
| Neoplasm Proteins | 12 | 2017 | 58 | 2.710 |
Why?
|
| Neoplastic Stem Cells | 8 | 2020 | 21 | 2.620 |
Why?
|
| Bone Marrow Neoplasms | 15 | 2014 | 15 | 2.590 |
Why?
|
| Carcinoma, Ductal, Breast | 18 | 2019 | 19 | 2.500 |
Why?
|
| Prospective Studies | 53 | 2023 | 174 | 2.330 |
Why?
|
| Chemotherapy, Adjuvant | 33 | 2022 | 36 | 2.290 |
Why?
|
| Retrospective Studies | 42 | 2022 | 120 | 2.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2020 | 111 | 2.220 |
Why?
|
| Pregnancy | 42 | 2022 | 113 | 2.210 |
Why?
|
| Anxiety | 6 | 2021 | 12 | 2.210 |
Why?
|
| Membrane Proteins | 20 | 2020 | 101 | 2.160 |
Why?
|
| Diphosphonates | 10 | 2021 | 11 | 2.050 |
Why?
|
| Lymph Nodes | 19 | 2021 | 30 | 1.960 |
Why?
|
| Receptors, Estrogen | 26 | 2021 | 35 | 1.900 |
Why?
|
| Disease-Free Survival | 37 | 2022 | 54 | 1.860 |
Why?
|
| Brain Neoplasms | 6 | 2023 | 26 | 1.730 |
Why?
|
| Young Adult | 41 | 2021 | 345 | 1.670 |
Why?
|
| Treatment Outcome | 37 | 2023 | 115 | 1.630 |
Why?
|
| Aged, 80 and over | 37 | 2021 | 206 | 1.610 |
Why?
|
| Vulvar Neoplasms | 8 | 2022 | 8 | 1.530 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 9 | 2021 | 9 | 1.520 |
Why?
|
| Neoadjuvant Therapy | 25 | 2023 | 27 | 1.520 |
Why?
|
| Lymphatic Metastasis | 22 | 2022 | 24 | 1.500 |
Why?
|
| Cesarean Section | 7 | 2021 | 7 | 1.500 |
Why?
|
| Triple Negative Breast Neoplasms | 7 | 2023 | 11 | 1.480 |
Why?
|
| Uterine Cervical Neoplasms | 7 | 2022 | 10 | 1.470 |
Why?
|
| Endometrial Neoplasms | 5 | 2014 | 6 | 1.390 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2021 | 29 | 1.380 |
Why?
|
| Apoptosis | 11 | 2020 | 94 | 1.380 |
Why?
|
| Follow-Up Studies | 32 | 2020 | 99 | 1.340 |
Why?
|
| Immunohistochemistry | 27 | 2019 | 78 | 1.280 |
Why?
|
| Imidazoles | 7 | 2013 | 12 | 1.240 |
Why?
|
| Cystadenocarcinoma, Serous | 7 | 2019 | 7 | 1.230 |
Why?
|
| Disease Progression | 11 | 2020 | 72 | 1.220 |
Why?
|
| Aromatase Inhibitors | 10 | 2020 | 10 | 1.210 |
Why?
|
| Germany | 30 | 2022 | 251 | 1.200 |
Why?
|
| Bone Neoplasms | 7 | 2016 | 13 | 1.200 |
Why?
|
| Music Therapy | 4 | 2021 | 4 | 1.190 |
Why?
|
| Infertility, Female | 7 | 2022 | 8 | 1.190 |
Why?
|
| Carcinoma, Lobular | 12 | 2019 | 12 | 1.170 |
Why?
|
| Epithelial Cells | 10 | 2019 | 47 | 1.150 |
Why?
|
| Risk Factors | 23 | 2020 | 265 | 1.110 |
Why?
|
| Cell Line, Tumor | 26 | 2020 | 161 | 1.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2017 | 7 | 1.100 |
Why?
|
| Carcinoma | 6 | 2021 | 10 | 1.090 |
Why?
|
| Cell Proliferation | 23 | 2020 | 129 | 1.070 |
Why?
|
| Estrogen Receptor beta | 4 | 2014 | 7 | 1.070 |
Why?
|
| Neoplasm, Residual | 10 | 2016 | 27 | 1.070 |
Why?
|
| Trastuzumab | 13 | 2023 | 14 | 1.060 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2022 | 552 | 1.040 |
Why?
|
| Bevacizumab | 7 | 2020 | 8 | 1.040 |
Why?
|
| Neoplasm Grading | 17 | 2019 | 20 | 1.040 |
Why?
|
| Fertility | 6 | 2011 | 6 | 1.040 |
Why?
|
| Leukapheresis | 4 | 2019 | 4 | 1.020 |
Why?
|
| Postmenopause | 11 | 2020 | 11 | 0.990 |
Why?
|
| Estrogen Receptor alpha | 7 | 2019 | 9 | 0.990 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 13 | 2013 | 93 | 0.980 |
Why?
|
| Ovary | 7 | 2019 | 9 | 0.970 |
Why?
|
| Kaplan-Meier Estimate | 24 | 2019 | 33 | 0.970 |
Why?
|
| Stress, Psychological | 2 | 2021 | 7 | 0.970 |
Why?
|
| Mucin-1 | 4 | 2016 | 6 | 0.950 |
Why?
|
| Neoplasms | 8 | 2020 | 135 | 0.930 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2023 | 529 | 0.920 |
Why?
|
| Oocytes | 5 | 2022 | 14 | 0.920 |
Why?
|
| Cell Separation | 5 | 2017 | 30 | 0.910 |
Why?
|
| Time Factors | 17 | 2020 | 115 | 0.910 |
Why?
|
| Registries | 12 | 2022 | 25 | 0.900 |
Why?
|
| Carboplatin | 5 | 2019 | 8 | 0.890 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2020 | 5 | 0.890 |
Why?
|
| Endometriosis | 5 | 2022 | 5 | 0.880 |
Why?
|
| Genital Neoplasms, Female | 4 | 2016 | 4 | 0.880 |
Why?
|
| Sentinel Lymph Node Biopsy | 11 | 2022 | 11 | 0.870 |
Why?
|
| Adenosine Triphosphate | 4 | 2012 | 56 | 0.870 |
Why?
|
| Antibodies, Monoclonal, Humanized | 13 | 2023 | 18 | 0.860 |
Why?
|
| Cyclophosphamide | 17 | 2023 | 25 | 0.840 |
Why?
|
| Predictive Value of Tests | 19 | 2019 | 52 | 0.810 |
Why?
|
| Survival Rate | 15 | 2020 | 36 | 0.810 |
Why?
|
| Lymph Node Excision | 10 | 2021 | 11 | 0.800 |
Why?
|
| Genes, BRCA2 | 1 | 2021 | 5 | 0.800 |
Why?
|
| Catheters | 1 | 2021 | 1 | 0.800 |
Why?
|
| Vascular Access Devices | 1 | 2021 | 1 | 0.800 |
Why?
|
| Genes, BRCA1 | 1 | 2021 | 8 | 0.800 |
Why?
|
| Mutation | 11 | 2022 | 608 | 0.800 |
Why?
|
| Breast | 11 | 2020 | 16 | 0.780 |
Why?
|
| Gene Expression Profiling | 7 | 2020 | 345 | 0.760 |
Why?
|
| Length of Stay | 1 | 2020 | 2 | 0.750 |
Why?
|
| Paclitaxel | 5 | 2023 | 5 | 0.740 |
Why?
|
| Clinical Trials as Topic | 9 | 2022 | 18 | 0.740 |
Why?
|
| Cell Count | 11 | 2019 | 18 | 0.740 |
Why?
|
| Hypoxia | 1 | 2020 | 6 | 0.740 |
Why?
|
| MicroRNAs | 3 | 2018 | 82 | 0.730 |
Why?
|
| Progestins | 5 | 2017 | 5 | 0.730 |
Why?
|
| BRCA2 Protein | 5 | 2022 | 14 | 0.730 |
Why?
|
| BRCA1 Protein | 5 | 2022 | 19 | 0.720 |
Why?
|
| Epithelial Cell Adhesion Molecule | 6 | 2023 | 7 | 0.700 |
Why?
|
| Osteonecrosis | 2 | 2009 | 7 | 0.700 |
Why?
|
| Breast Neoplasms, Male | 4 | 2022 | 5 | 0.700 |
Why?
|
| DNA, Neoplasm | 5 | 2019 | 23 | 0.680 |
Why?
|
| Male | 24 | 2023 | 1811 | 0.660 |
Why?
|
| Bone Marrow Cells | 6 | 2013 | 26 | 0.640 |
Why?
|
| Survival Analysis | 17 | 2020 | 39 | 0.630 |
Why?
|
| Oocyte Retrieval | 4 | 2017 | 5 | 0.630 |
Why?
|
| Patient Selection | 5 | 2020 | 8 | 0.620 |
Why?
|
| Estrogens | 6 | 2013 | 9 | 0.620 |
Why?
|
| Proportional Hazards Models | 17 | 2023 | 38 | 0.620 |
Why?
|
| Antigens, Neoplasm | 7 | 2020 | 38 | 0.610 |
Why?
|
| Parturition | 4 | 2021 | 4 | 0.610 |
Why?
|
| Cohort Studies | 14 | 2021 | 191 | 0.600 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2015 | 3 | 0.600 |
Why?
|
| Case-Control Studies | 11 | 2021 | 322 | 0.600 |
Why?
|
| Adolescent | 14 | 2021 | 493 | 0.590 |
Why?
|
| Antibodies, Monoclonal | 7 | 2020 | 21 | 0.590 |
Why?
|
| Epirubicin | 12 | 2023 | 13 | 0.570 |
Why?
|
| Lymphocyte Subsets | 1 | 2016 | 5 | 0.570 |
Why?
|
| Immunity, Cellular | 1 | 2016 | 12 | 0.570 |
Why?
|
| Premenopause | 3 | 2012 | 3 | 0.570 |
Why?
|
| Music | 3 | 2021 | 4 | 0.560 |
Why?
|
| CA-125 Antigen | 3 | 2015 | 3 | 0.560 |
Why?
|
| Anti-Mullerian Hormone | 3 | 2012 | 3 | 0.560 |
Why?
|
| Progesterone | 6 | 2015 | 7 | 0.560 |
Why?
|
| Neoplasms, Hormone-Dependent | 4 | 2012 | 4 | 0.560 |
Why?
|
| SOXB1 Transcription Factors | 4 | 2021 | 8 | 0.560 |
Why?
|
| RNA, Messenger | 13 | 2019 | 263 | 0.550 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2018 | 5 | 0.550 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2020 | 6 | 0.550 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2022 | 50 | 0.540 |
Why?
|
| Taxoids | 7 | 2022 | 7 | 0.540 |
Why?
|
| Antineoplastic Agents, Hormonal | 6 | 2020 | 6 | 0.530 |
Why?
|
| DNA Methylation | 3 | 2020 | 186 | 0.530 |
Why?
|
| Quality of Life | 6 | 2023 | 21 | 0.530 |
Why?
|
| Antigens, Differentiation | 2 | 2012 | 3 | 0.510 |
Why?
|
| Hysteroscopy | 2 | 2015 | 2 | 0.510 |
Why?
|
| Phosphorylation | 5 | 2020 | 51 | 0.510 |
Why?
|
| Carcinoma, Medullary | 2 | 2012 | 2 | 0.510 |
Why?
|
| Single-Cell Analysis | 6 | 2019 | 67 | 0.510 |
Why?
|
| Abortion, Spontaneous | 4 | 2022 | 7 | 0.510 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2014 | 1 | 0.500 |
Why?
|
| Mastectomy | 6 | 2021 | 6 | 0.490 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 99 | 0.480 |
Why?
|
| Adenocarcinoma | 2 | 2014 | 13 | 0.480 |
Why?
|
| Bone Density Conservation Agents | 1 | 2013 | 2 | 0.480 |
Why?
|
| Pregnancy Outcome | 8 | 2022 | 11 | 0.480 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2012 | 12 | 0.470 |
Why?
|
| Hodgkin Disease | 2 | 2012 | 21 | 0.470 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2013 | 1 | 0.470 |
Why?
|
| Fertility Preservation | 3 | 2019 | 3 | 0.470 |
Why?
|
| Fluorouracil | 8 | 2020 | 8 | 0.470 |
Why?
|
| Transcription Factors | 2 | 2017 | 256 | 0.470 |
Why?
|
| Keratins | 8 | 2015 | 10 | 0.460 |
Why?
|
| Flow Cytometry | 5 | 2018 | 71 | 0.460 |
Why?
|
| Multivariate Analysis | 14 | 2019 | 30 | 0.450 |
Why?
|
| Models, Biological | 3 | 2010 | 115 | 0.450 |
Why?
|
| Reproducibility of Results | 10 | 2021 | 92 | 0.440 |
Why?
|
| Tamoxifen | 4 | 2018 | 8 | 0.440 |
Why?
|
| Estradiol | 5 | 2017 | 5 | 0.440 |
Why?
|
| Proteomics | 3 | 2008 | 77 | 0.440 |
Why?
|
| Neoplasm Invasiveness | 14 | 2019 | 22 | 0.430 |
Why?
|
| Endometrium | 4 | 2022 | 4 | 0.430 |
Why?
|
| Ki-67 Antigen | 6 | 2015 | 8 | 0.420 |
Why?
|
| Age Factors | 5 | 2020 | 56 | 0.420 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 4 | 0.420 |
Why?
|
| Bone and Bones | 1 | 2011 | 15 | 0.420 |
Why?
|
| Homeodomain Proteins | 2 | 2011 | 56 | 0.410 |
Why?
|
| Diabetes, Gestational | 2 | 2021 | 2 | 0.400 |
Why?
|
| Surveys and Questionnaires | 9 | 2021 | 31 | 0.400 |
Why?
|
| Mother-Child Relations | 2 | 2021 | 2 | 0.400 |
Why?
|
| Singing | 2 | 2021 | 2 | 0.400 |
Why?
|
| MCF-7 Cells | 10 | 2017 | 16 | 0.400 |
Why?
|
| Mothers | 2 | 2021 | 8 | 0.400 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 3 | 0.400 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 27 | 0.390 |
Why?
|
| Sentinel Lymph Node | 3 | 2021 | 3 | 0.390 |
Why?
|
| Carcinoma, Small Cell | 1 | 2010 | 1 | 0.390 |
Why?
|
| Signal Transduction | 7 | 2019 | 261 | 0.390 |
Why?
|
| Biopsy | 6 | 2020 | 31 | 0.380 |
Why?
|
| Peritoneum | 1 | 2010 | 2 | 0.380 |
Why?
|
| Extracellular Matrix | 2 | 2013 | 11 | 0.370 |
Why?
|
| Physicians | 2 | 2023 | 2 | 0.370 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 4 | 2017 | 5 | 0.360 |
Why?
|
| Musculoskeletal Pain | 2 | 2020 | 2 | 0.360 |
Why?
|
| Jaw Diseases | 1 | 2009 | 1 | 0.360 |
Why?
|
| Animals | 13 | 2020 | 1545 | 0.360 |
Why?
|
| Serum Albumin, Bovine | 1 | 2009 | 3 | 0.350 |
Why?
|
| Medication Adherence | 3 | 2018 | 5 | 0.350 |
Why?
|
| Postpartum Period | 2 | 2021 | 2 | 0.350 |
Why?
|
| Prostatic Neoplasms | 3 | 2015 | 18 | 0.350 |
Why?
|
| Laminin | 1 | 2009 | 4 | 0.350 |
Why?
|
| Bone Marrow Examination | 3 | 2015 | 3 | 0.350 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2019 | 12 | 0.340 |
Why?
|
| Jaw | 1 | 2009 | 1 | 0.340 |
Why?
|
| Pregnancy Complications, Neoplastic | 3 | 2020 | 4 | 0.340 |
Why?
|
| Complementary Therapies | 2 | 2020 | 3 | 0.340 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2022 | 3 | 0.340 |
Why?
|
| Transcriptome | 4 | 2020 | 201 | 0.340 |
Why?
|
| Nomograms | 2 | 2018 | 2 | 0.340 |
Why?
|
| Cryopreservation | 8 | 2022 | 10 | 0.340 |
Why?
|
| Medroxyprogesterone Acetate | 6 | 2013 | 7 | 0.330 |
Why?
|
| Anthracyclines | 5 | 2023 | 11 | 0.330 |
Why?
|
| Mastectomy, Segmental | 4 | 2021 | 4 | 0.320 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2015 | 17 | 0.320 |
Why?
|
| Cisplatin | 1 | 2008 | 20 | 0.320 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2018 | 2 | 0.320 |
Why?
|
| Oncolytic Virotherapy | 3 | 2013 | 3 | 0.320 |
Why?
|
| Tumor Burden | 7 | 2016 | 7 | 0.320 |
Why?
|
| Chromosomes, Human | 2 | 2005 | 12 | 0.310 |
Why?
|
| Liquid Biopsy | 4 | 2021 | 5 | 0.310 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2020 | 2 | 0.300 |
Why?
|
| Osteoporosis | 3 | 2011 | 6 | 0.300 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2020 | 18 | 0.290 |
Why?
|
| Peritoneal Neoplasms | 2 | 2020 | 2 | 0.290 |
Why?
|
| Pregnancy Complications | 3 | 2016 | 6 | 0.290 |
Why?
|
| Mice | 8 | 2020 | 737 | 0.290 |
Why?
|
| Biopsy, Large-Core Needle | 2 | 2020 | 2 | 0.290 |
Why?
|
| Syndecan-1 | 2 | 2017 | 2 | 0.280 |
Why?
|
| Biomarkers | 4 | 2018 | 188 | 0.280 |
Why?
|
| Reference Standards | 5 | 2018 | 17 | 0.280 |
Why?
|
| Gynecologic Surgical Procedures | 2 | 2016 | 2 | 0.280 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2018 | 39 | 0.280 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2019 | 9 | 0.280 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2022 | 9 | 0.270 |
Why?
|
| Gonadotropin-Releasing Hormone | 4 | 2019 | 4 | 0.270 |
Why?
|
| Prevalence | 8 | 2018 | 46 | 0.270 |
Why?
|
| Doxorubicin | 3 | 2016 | 13 | 0.270 |
Why?
|
| Premature Birth | 2 | 2022 | 8 | 0.260 |
Why?
|
| Uterus | 3 | 2022 | 4 | 0.260 |
Why?
|
| DNA-Binding Proteins | 3 | 2017 | 139 | 0.260 |
Why?
|
| Killer Cells, Natural | 3 | 2022 | 24 | 0.260 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2017 | 2 | 0.260 |
Why?
|
| Ultrasonography | 4 | 2016 | 16 | 0.260 |
Why?
|
| Lymphoma | 2 | 2011 | 14 | 0.260 |
Why?
|
| Combined Modality Therapy | 6 | 2019 | 20 | 0.260 |
Why?
|
| Genomics | 3 | 2014 | 143 | 0.260 |
Why?
|
| Delivery, Obstetric | 3 | 2020 | 3 | 0.250 |
Why?
|
| Deoxycytidine | 4 | 2020 | 6 | 0.250 |
Why?
|
| Metabolome | 2 | 2015 | 18 | 0.250 |
Why?
|
| Pregnant Women | 2 | 2021 | 2 | 0.240 |
Why?
|
| Object Attachment | 2 | 2021 | 2 | 0.240 |
Why?
|
| Neovascularization, Pathologic | 3 | 2015 | 6 | 0.240 |
Why?
|
| Obstetric Labor Complications | 2 | 2018 | 2 | 0.240 |
Why?
|
| Postoperative Period | 3 | 2019 | 4 | 0.240 |
Why?
|
| Cell Movement | 5 | 2020 | 45 | 0.240 |
Why?
|
| Quinazolines | 3 | 2015 | 3 | 0.240 |
Why?
|
| Incidence | 6 | 2019 | 54 | 0.240 |
Why?
|
| Infant, Newborn | 7 | 2022 | 119 | 0.240 |
Why?
|
| Health Care Costs | 2 | 2015 | 2 | 0.230 |
Why?
|
| Germ-Line Mutation | 3 | 2023 | 54 | 0.230 |
Why?
|
| Immunoconjugates | 1 | 2023 | 1 | 0.230 |
Why?
|
| Precision Medicine | 1 | 2023 | 22 | 0.230 |
Why?
|
| Obstetrics | 2 | 2021 | 2 | 0.230 |
Why?
|
| Biopsy, Needle | 5 | 2013 | 7 | 0.230 |
Why?
|
| Receptors, Steroid | 2 | 2021 | 4 | 0.230 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2020 | 4 | 0.220 |
Why?
|
| Laparoscopy | 2 | 2014 | 3 | 0.220 |
Why?
|
| Sirolimus | 2 | 2014 | 6 | 0.220 |
Why?
|
| Comparative Genomic Hybridization | 4 | 2015 | 24 | 0.220 |
Why?
|
| Leukopenia | 1 | 2022 | 3 | 0.220 |
Why?
|
| Cell Differentiation | 4 | 2020 | 199 | 0.220 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 170 | 0.220 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2016 | 39 | 0.220 |
Why?
|
| Phenotype | 5 | 2017 | 479 | 0.220 |
Why?
|
| Clinical Studies as Topic | 1 | 2022 | 1 | 0.220 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 83 | 0.220 |
Why?
|
| Fallopian Tube Neoplasms | 2 | 2020 | 2 | 0.220 |
Why?
|
| Abnormalities, Drug-Induced | 2 | 2012 | 3 | 0.220 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 18 | 0.220 |
Why?
|
| Risk | 5 | 2022 | 35 | 0.220 |
Why?
|
| Gametogenesis | 1 | 2022 | 1 | 0.220 |
Why?
|
| Contraceptive Agents, Female | 2 | 2012 | 3 | 0.210 |
Why?
|
| Everolimus | 3 | 2017 | 3 | 0.210 |
Why?
|
| Logistic Models | 5 | 2015 | 26 | 0.210 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 11 | 0.210 |
Why?
|
| Patient Care | 2 | 2023 | 3 | 0.210 |
Why?
|
| Bone Density | 2 | 2011 | 2 | 0.210 |
Why?
|
| Cells, Cultured | 4 | 2015 | 261 | 0.210 |
Why?
|
| Dyspareunia | 1 | 2021 | 1 | 0.210 |
Why?
|
| Circulating Tumor DNA | 1 | 2021 | 6 | 0.210 |
Why?
|
| Pandemics | 1 | 2021 | 25 | 0.210 |
Why?
|
| Postoperative Complications | 2 | 2019 | 14 | 0.210 |
Why?
|
| Depression, Postpartum | 1 | 2021 | 1 | 0.210 |
Why?
|
| Breast Feeding | 3 | 2022 | 4 | 0.200 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 1 | 0.200 |
Why?
|
| Administration, Metronomic | 1 | 2021 | 1 | 0.200 |
Why?
|
| Administration, Oral | 1 | 2021 | 6 | 0.200 |
Why?
|
| Norethindrone | 4 | 2013 | 5 | 0.200 |
Why?
|
| Papillomavirus Vaccines | 1 | 2021 | 2 | 0.200 |
Why?
|
| Ultrasonography, Mammary | 3 | 2011 | 3 | 0.200 |
Why?
|
| Carbonic Anhydrase IX | 2 | 2019 | 2 | 0.200 |
Why?
|
| Hyperthermia, Induced | 2 | 2011 | 2 | 0.200 |
Why?
|
| Heart Rate | 1 | 2021 | 7 | 0.200 |
Why?
|
| Blood Pressure | 1 | 2021 | 29 | 0.200 |
Why?
|
| Europe | 4 | 2014 | 60 | 0.200 |
Why?
|
| Neuregulin-1 | 1 | 2020 | 1 | 0.200 |
Why?
|
| Personality | 1 | 2020 | 1 | 0.190 |
Why?
|
| Analgesia, Epidural | 1 | 2020 | 1 | 0.190 |
Why?
|
| Genetic Association Studies | 3 | 2019 | 122 | 0.190 |
Why?
|
| Endometritis | 1 | 2020 | 1 | 0.190 |
Why?
|
| Abortion, Habitual | 1 | 2020 | 2 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 17 | 0.190 |
Why?
|
| Workflow | 2 | 2017 | 21 | 0.190 |
Why?
|
| Integrative Medicine | 2 | 2017 | 2 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 6 | 2020 | 34 | 0.190 |
Why?
|
| Drug Screening Assays, Antitumor | 5 | 2012 | 13 | 0.190 |
Why?
|
| Perioperative Period | 1 | 2020 | 1 | 0.190 |
Why?
|
| Visual Analog Scale | 1 | 2020 | 1 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2014 | 32 | 0.190 |
Why?
|
| Down-Regulation | 2 | 2012 | 55 | 0.190 |
Why?
|
| Pilot Projects | 2 | 2018 | 16 | 0.190 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2020 | 1 | 0.180 |
Why?
|
| Radiography | 3 | 2010 | 11 | 0.180 |
Why?
|
| Ovulation Induction | 2 | 2017 | 3 | 0.180 |
Why?
|
| Stromal Cells | 2 | 2017 | 13 | 0.180 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 3 | 0.180 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2019 | 5 | 0.180 |
Why?
|
| Receptors, Androgen | 1 | 2019 | 8 | 0.180 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2019 | 1 | 0.180 |
Why?
|
| GTP Phosphohydrolases | 1 | 2019 | 11 | 0.180 |
Why?
|
| Gynecology | 1 | 2019 | 1 | 0.180 |
Why?
|
| Students, Medical | 1 | 2019 | 1 | 0.180 |
Why?
|
| Education, Medical | 1 | 2019 | 2 | 0.180 |
Why?
|
| Axilla | 4 | 2018 | 4 | 0.180 |
Why?
|
| Patient Compliance | 1 | 2019 | 1 | 0.180 |
Why?
|
| Genetic Testing | 2 | 2016 | 66 | 0.180 |
Why?
|
| Quantum Dots | 1 | 2019 | 2 | 0.180 |
Why?
|
| Cesarean Section, Repeat | 1 | 2019 | 1 | 0.180 |
Why?
|
| Graphite | 1 | 2019 | 3 | 0.180 |
Why?
|
| Esthetics | 1 | 2019 | 1 | 0.180 |
Why?
|
| Postpartum Hemorrhage | 1 | 2019 | 1 | 0.180 |
Why?
|
| Kidney Cortex Necrosis | 1 | 2019 | 1 | 0.180 |
Why?
|
| Tranexamic Acid | 1 | 2019 | 1 | 0.180 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 4 | 0.180 |
Why?
|
| Fertilization in Vitro | 2 | 2017 | 3 | 0.180 |
Why?
|
| Keratin-18 | 2 | 2016 | 2 | 0.180 |
Why?
|
| Labor, Induced | 1 | 2019 | 1 | 0.180 |
Why?
|
| Labor, Obstetric | 1 | 2019 | 2 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2022 | 11 | 0.180 |
Why?
|
| Analgesia | 1 | 2019 | 1 | 0.180 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 27 | 0.170 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2019 | 2 | 0.170 |
Why?
|
| Peptide Fragments | 2 | 2016 | 26 | 0.170 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2019 | 1 | 0.170 |
Why?
|
| Leiomyomatosis | 1 | 2019 | 1 | 0.170 |
Why?
|
| Uterine Neoplasms | 1 | 2019 | 2 | 0.170 |
Why?
|
| Hormone Replacement Therapy | 1 | 2019 | 2 | 0.170 |
Why?
|
| Inflammation | 1 | 2020 | 179 | 0.170 |
Why?
|
| Computational Biology | 1 | 2020 | 164 | 0.170 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 3 | 0.170 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2018 | 1 | 0.170 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2018 | 3 | 0.170 |
Why?
|
| Mice, SCID | 4 | 2020 | 12 | 0.170 |
Why?
|
| Gene Amplification | 5 | 2013 | 8 | 0.160 |
Why?
|
| Androstadienes | 1 | 2018 | 3 | 0.160 |
Why?
|
| Filtration | 1 | 2018 | 2 | 0.160 |
Why?
|
| Metabolomics | 2 | 2015 | 24 | 0.160 |
Why?
|
| Mice, Inbred NOD | 4 | 2020 | 11 | 0.160 |
Why?
|
| Weight Gain | 1 | 2018 | 5 | 0.160 |
Why?
|
| Weight Loss | 1 | 2018 | 9 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2013 | 20 | 0.160 |
Why?
|
| Stem Cells | 1 | 2018 | 40 | 0.160 |
Why?
|
| Cell Line | 5 | 2020 | 137 | 0.160 |
Why?
|
| Hysterectomy | 2 | 2021 | 2 | 0.160 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2017 | 4 | 0.150 |
Why?
|
| Gene Expression | 5 | 2019 | 138 | 0.150 |
Why?
|
| Heterozygote | 3 | 2023 | 94 | 0.150 |
Why?
|
| Mitoxantrone | 1 | 1997 | 2 | 0.150 |
Why?
|
| Chemokine CXCL1 | 1 | 2017 | 1 | 0.150 |
Why?
|
| Trophoblasts | 1 | 2017 | 2 | 0.150 |
Why?
|
| Gene Frequency | 2 | 2014 | 120 | 0.150 |
Why?
|
| Proto-Oncogenes | 1 | 2017 | 10 | 0.150 |
Why?
|
| Ultrasonography, Prenatal | 3 | 2006 | 6 | 0.150 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2015 | 23 | 0.150 |
Why?
|
| Palpation | 1 | 2016 | 1 | 0.150 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2016 | 3 | 0.150 |
Why?
|
| Margins of Excision | 1 | 2016 | 1 | 0.150 |
Why?
|
| Ultrasonography, Interventional | 3 | 2011 | 3 | 0.150 |
Why?
|
| Carcinosarcoma | 1 | 2016 | 1 | 0.150 |
Why?
|
| Leiomyosarcoma | 1 | 2016 | 1 | 0.150 |
Why?
|
| Vulva | 1 | 2016 | 1 | 0.150 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 7 | 0.150 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2016 | 16 | 0.150 |
Why?
|
| ErbB Receptors | 2 | 2017 | 11 | 0.150 |
Why?
|
| Immunoenzyme Techniques | 3 | 2013 | 8 | 0.150 |
Why?
|
| Nitriles | 1 | 2016 | 4 | 0.150 |
Why?
|
| Triazoles | 1 | 2016 | 3 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2016 | 103 | 0.150 |
Why?
|
| Placenta Growth Factor | 1 | 2016 | 1 | 0.150 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 1 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2016 | 2 | 0.150 |
Why?
|
| Pre-Eclampsia | 1 | 2016 | 3 | 0.150 |
Why?
|
| fas Receptor | 3 | 2015 | 6 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2019 | 20 | 0.140 |
Why?
|
| Immunologic Surveillance | 1 | 2016 | 2 | 0.140 |
Why?
|
| Fetofetal Transfusion | 2 | 2007 | 3 | 0.140 |
Why?
|
| Transfection | 3 | 2013 | 51 | 0.140 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2016 | 4 | 0.140 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 11 | 0.140 |
Why?
|
| Child | 5 | 2021 | 557 | 0.140 |
Why?
|
| RANK Ligand | 2 | 2014 | 3 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2013 | 42 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 12 | 0.140 |
Why?
|
| Antigens, Surface | 1 | 2015 | 8 | 0.140 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 3 | 0.140 |
Why?
|
| Drug Administration Schedule | 3 | 2012 | 7 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 13 | 0.140 |
Why?
|
| Critical Pathways | 1 | 2015 | 1 | 0.140 |
Why?
|
| Documentation | 1 | 2015 | 3 | 0.140 |
Why?
|
| Hepatitis C | 1 | 2015 | 1 | 0.140 |
Why?
|
| Tetraspanin 28 | 1 | 2015 | 1 | 0.140 |
Why?
|
| Claudin-1 | 1 | 2015 | 1 | 0.140 |
Why?
|
| Virus Internalization | 1 | 2015 | 3 | 0.140 |
Why?
|
| Hepacivirus | 1 | 2015 | 5 | 0.140 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2012 | 5 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 2 | 2014 | 249 | 0.140 |
Why?
|
| Hyponatremia | 1 | 2015 | 1 | 0.130 |
Why?
|
| Pulmonary Edema | 1 | 2015 | 1 | 0.130 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 38 | 0.130 |
Why?
|
| Neuroendocrine Tumors | 1 | 2015 | 2 | 0.130 |
Why?
|
| Oogenesis | 1 | 2015 | 5 | 0.130 |
Why?
|
| Obstetric Labor, Premature | 2 | 2012 | 2 | 0.130 |
Why?
|
| Survivors | 2 | 2012 | 3 | 0.130 |
Why?
|
| Genes, erbB-2 | 2 | 2005 | 4 | 0.130 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2020 | 9 | 0.130 |
Why?
|
| Cystadenoma, Serous | 1 | 2015 | 1 | 0.130 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2014 | 4 | 0.130 |
Why?
|
| Evidence-Based Medicine | 2 | 2014 | 4 | 0.130 |
Why?
|
| Retinal Dehydrogenase | 2 | 2012 | 5 | 0.130 |
Why?
|
| Ovariectomy | 2 | 2011 | 3 | 0.130 |
Why?
|
| Isoenzymes | 2 | 2012 | 15 | 0.130 |
Why?
|
| Pathology, Molecular | 1 | 2014 | 6 | 0.130 |
Why?
|
| Risk Assessment | 4 | 2019 | 47 | 0.130 |
Why?
|
| Estetrol | 1 | 2014 | 1 | 0.130 |
Why?
|
| Oncolytic Viruses | 2 | 2011 | 2 | 0.130 |
Why?
|
| Cytokines | 1 | 2015 | 75 | 0.130 |
Why?
|
| Acid Ceramidase | 1 | 2014 | 3 | 0.130 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 11 | 0.130 |
Why?
|
| Proteins | 1 | 2015 | 77 | 0.130 |
Why?
|
| Osteoprotegerin | 1 | 2014 | 1 | 0.120 |
Why?
|
| Medical Oncology | 1 | 2014 | 5 | 0.120 |
Why?
|
| Fetal Growth Retardation | 2 | 2012 | 15 | 0.120 |
Why?
|
| Recurrence | 2 | 2011 | 20 | 0.120 |
Why?
|
| Oncogene Proteins | 1 | 2014 | 13 | 0.120 |
Why?
|
| Cell Adhesion Molecules | 2 | 2015 | 20 | 0.120 |
Why?
|
| Microfilament Proteins | 1 | 2014 | 17 | 0.120 |
Why?
|
| Rectal Diseases | 1 | 2014 | 1 | 0.120 |
Why?
|
| Uterine Diseases | 1 | 2014 | 1 | 0.120 |
Why?
|
| Melanoma | 1 | 2014 | 13 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2014 | 10 | 0.120 |
Why?
|
| Genotype | 3 | 2022 | 320 | 0.120 |
Why?
|
| Immunophenotyping | 2 | 2011 | 36 | 0.120 |
Why?
|
| Capecitabine | 3 | 2023 | 3 | 0.120 |
Why?
|
| Heterografts | 3 | 2020 | 4 | 0.120 |
Why?
|
| ROC Curve | 3 | 2019 | 12 | 0.120 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2013 | 1 | 0.120 |
Why?
|
| Up-Regulation | 2 | 2017 | 62 | 0.120 |
Why?
|
| Blotting, Western | 2 | 2013 | 38 | 0.120 |
Why?
|
| Osteoblasts | 1 | 2013 | 5 | 0.120 |
Why?
|
| Arthralgia | 3 | 2020 | 4 | 0.120 |
Why?
|
| United States | 1 | 2013 | 10 | 0.120 |
Why?
|
| Measles virus | 1 | 2013 | 1 | 0.120 |
Why?
|
| Pentosyltransferases | 1 | 2013 | 1 | 0.120 |
Why?
|
| Cytosine Deaminase | 1 | 2013 | 2 | 0.120 |
Why?
|
| Contraceptives, Oral, Synthetic | 1 | 2013 | 1 | 0.120 |
Why?
|
| Genetic Therapy | 1 | 2013 | 13 | 0.120 |
Why?
|
| Cause of Death | 1 | 2013 | 4 | 0.120 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2013 | 19 | 0.120 |
Why?
|
| Keratin-19 | 2 | 2011 | 2 | 0.110 |
Why?
|
| Amniotic Fluid | 2 | 2018 | 2 | 0.110 |
Why?
|
| Patient Satisfaction | 3 | 2019 | 3 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 2 | 2012 | 97 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 5 | 0.110 |
Why?
|
| Nandrolone | 1 | 2012 | 1 | 0.110 |
Why?
|
| Erythrocyte Transfusion | 1 | 2012 | 1 | 0.110 |
Why?
|
| Neuromuscular Blockade | 1 | 2012 | 1 | 0.110 |
Why?
|
| Curare | 1 | 2012 | 2 | 0.110 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2012 | 5 | 0.110 |
Why?
|
| Birth Weight | 1 | 2012 | 3 | 0.110 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2012 | 5 | 0.110 |
Why?
|
| Primary Cell Culture | 1 | 2012 | 11 | 0.110 |
Why?
|
| Chromosome Aberrations | 2 | 2023 | 44 | 0.110 |
Why?
|
| Mammary Glands, Human | 2 | 2009 | 2 | 0.110 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2012 | 1 | 0.110 |
Why?
|
| Megestrol | 1 | 2012 | 1 | 0.110 |
Why?
|
| Norpregnadienes | 1 | 2012 | 1 | 0.110 |
Why?
|
| Abnormalities, Radiation-Induced | 1 | 2012 | 1 | 0.110 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2012 | 2 | 0.110 |
Why?
|
| Twist-Related Protein 1 | 1 | 2012 | 2 | 0.110 |
Why?
|
| Protein Isoforms | 2 | 2009 | 37 | 0.110 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2012 | 2 | 0.110 |
Why?
|
| Cell Membrane | 1 | 2012 | 20 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 12 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2011 | 2 | 0.100 |
Why?
|
| Aftercare | 2 | 2021 | 2 | 0.100 |
Why?
|
| NF-kappa B | 1 | 2011 | 26 | 0.100 |
Why?
|
| Calcaneus | 1 | 2011 | 1 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2011 | 10 | 0.100 |
Why?
|
| Hospitals | 2 | 2022 | 4 | 0.100 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 2 | 0.100 |
Why?
|
| Carbonic Anhydrases | 1 | 2011 | 2 | 0.100 |
Why?
|
| Compartment Syndromes | 1 | 2011 | 1 | 0.100 |
Why?
|
| Patient Positioning | 1 | 2011 | 1 | 0.100 |
Why?
|
| Lower Extremity | 1 | 2011 | 4 | 0.100 |
Why?
|
| Endonucleases | 1 | 2011 | 6 | 0.100 |
Why?
|
| Alendronate | 1 | 2011 | 1 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2011 | 4 | 0.100 |
Why?
|
| Goserelin | 1 | 2011 | 1 | 0.100 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2011 | 4 | 0.100 |
Why?
|
| Neoplasm Seeding | 1 | 2011 | 1 | 0.100 |
Why?
|
| Glucuronosyltransferase | 1 | 2011 | 4 | 0.100 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2011 | 3 | 0.100 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 11 | 0.100 |
Why?
|
| Ovarian Function Tests | 1 | 2011 | 1 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2011 | 2 | 0.100 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2009 | 47 | 0.100 |
Why?
|
| Fertilization | 1 | 2011 | 2 | 0.100 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2011 | 17 | 0.100 |
Why?
|
| Access to Information | 1 | 2010 | 1 | 0.100 |
Why?
|
| Reimbursement Mechanisms | 1 | 2010 | 1 | 0.100 |
Why?
|
| National Health Programs | 1 | 2010 | 2 | 0.100 |
Why?
|
| Information Dissemination | 1 | 2010 | 3 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 68 | 0.100 |
Why?
|
| Embryonic Stem Cells | 1 | 2011 | 24 | 0.100 |
Why?
|
| Internet | 1 | 2010 | 19 | 0.100 |
Why?
|
| Tomography, Emission-Computed | 1 | 2010 | 2 | 0.100 |
Why?
|
| Etoposide | 1 | 2010 | 10 | 0.100 |
Why?
|
| Placenta | 2 | 2007 | 5 | 0.090 |
Why?
|
| Groin | 2 | 2021 | 2 | 0.090 |
Why?
|
| Endpoint Determination | 1 | 2010 | 2 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 4 | 0.090 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2008 | 12 | 0.090 |
Why?
|
| Deoxyuridine | 1 | 2009 | 1 | 0.090 |
Why?
|
| Cytidine | 1 | 2009 | 2 | 0.090 |
Why?
|
| Research Design | 1 | 2010 | 9 | 0.090 |
Why?
|
| Infant | 2 | 2020 | 267 | 0.090 |
Why?
|
| Rupture, Spontaneous | 1 | 2009 | 1 | 0.090 |
Why?
|
| Dental Care | 1 | 2009 | 1 | 0.090 |
Why?
|
| Microdissection | 2 | 2006 | 5 | 0.090 |
Why?
|
| Comorbidity | 1 | 2009 | 18 | 0.090 |
Why?
|
| Keratin-8 | 1 | 2009 | 1 | 0.090 |
Why?
|
| Mesoderm | 1 | 2009 | 4 | 0.090 |
Why?
|
| Cell Transdifferentiation | 1 | 2009 | 3 | 0.090 |
Why?
|
| Mifepristone | 1 | 2009 | 1 | 0.090 |
Why?
|
| Hormone Antagonists | 1 | 2009 | 2 | 0.090 |
Why?
|
| Microsurgery | 1 | 2009 | 1 | 0.090 |
Why?
|
| Breast Diseases | 1 | 2009 | 2 | 0.090 |
Why?
|
| Nipples | 1 | 2009 | 2 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2018 | 15 | 0.090 |
Why?
|
| Basement Membrane | 1 | 2009 | 1 | 0.090 |
Why?
|
| Collagen Type IV | 1 | 2009 | 2 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2008 | 6 | 0.090 |
Why?
|
| Karyotyping | 2 | 2008 | 28 | 0.080 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2008 | 1 | 0.080 |
Why?
|
| Mass Screening | 1 | 2008 | 3 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2019 | 20 | 0.080 |
Why?
|
| Cluster Analysis | 3 | 2015 | 62 | 0.080 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 2 | 0.080 |
Why?
|
| Platinum | 2 | 2023 | 2 | 0.080 |
Why?
|
| Alleles | 3 | 2014 | 221 | 0.080 |
Why?
|
| Tissue Array Analysis | 3 | 2013 | 10 | 0.080 |
Why?
|
| Drug Evaluation | 1 | 2008 | 1 | 0.080 |
Why?
|
| CD28 Antigens | 1 | 2008 | 6 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2008 | 21 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2008 | 3 | 0.080 |
Why?
|
| Hydrocortisone | 2 | 2019 | 3 | 0.080 |
Why?
|
| Saliva | 2 | 2019 | 4 | 0.080 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2008 | 3 | 0.080 |
Why?
|
| Ribose | 1 | 2007 | 1 | 0.080 |
Why?
|
| S-Adenosylmethionine | 1 | 2007 | 1 | 0.080 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 2007 | 2 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 43 | 0.080 |
Why?
|
| Pregnancy, Multiple | 2 | 2004 | 3 | 0.080 |
Why?
|
| Ribonucleosides | 1 | 2007 | 2 | 0.080 |
Why?
|
| Ligaments | 1 | 2007 | 1 | 0.080 |
Why?
|
| Muscle, Smooth | 1 | 2007 | 1 | 0.080 |
Why?
|
| Uterine Prolapse | 1 | 2007 | 1 | 0.080 |
Why?
|
| Chorion | 1 | 2007 | 1 | 0.080 |
Why?
|
| Fetal Distress | 1 | 2007 | 1 | 0.080 |
Why?
|
| Actins | 1 | 2007 | 13 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 98 | 0.080 |
Why?
|
| Receptors, LH | 2 | 2004 | 2 | 0.080 |
Why?
|
| RNA, Neoplasm | 3 | 2015 | 9 | 0.080 |
Why?
|
| Polyethylene Glycols | 2 | 2017 | 7 | 0.080 |
Why?
|
| Protein Array Analysis | 1 | 2007 | 11 | 0.070 |
Why?
|
| Fibroadenoma | 1 | 2006 | 1 | 0.070 |
Why?
|
| Acute Disease | 2 | 2015 | 17 | 0.070 |
Why?
|
| Meconium | 1 | 2006 | 1 | 0.070 |
Why?
|
| Likelihood Functions | 2 | 2018 | 18 | 0.070 |
Why?
|
| Carcinoma in Situ | 1 | 2006 | 1 | 0.070 |
Why?
|
| Immunomagnetic Separation | 2 | 2018 | 3 | 0.070 |
Why?
|
| Zebrafish | 2 | 2017 | 57 | 0.070 |
Why?
|
| Lasers | 1 | 2006 | 7 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2006 | 50 | 0.070 |
Why?
|
| Cytogenetic Analysis | 2 | 2004 | 13 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 2 | 2017 | 32 | 0.070 |
Why?
|
| Chickenpox | 1 | 2006 | 2 | 0.070 |
Why?
|
| Colon | 1 | 2006 | 8 | 0.070 |
Why?
|
| Fetal Diseases | 1 | 2006 | 7 | 0.070 |
Why?
|
| Cysts | 1 | 2006 | 6 | 0.070 |
Why?
|
| Immunoblotting | 2 | 2015 | 14 | 0.070 |
Why?
|
| Cathepsin D | 1 | 2005 | 1 | 0.070 |
Why?
|
| Mastectomy, Modified Radical | 1 | 2005 | 1 | 0.070 |
Why?
|
| Ploidies | 1 | 2005 | 3 | 0.070 |
Why?
|
| Genes, p53 | 1 | 2005 | 8 | 0.070 |
Why?
|
| Physical Examination | 1 | 2005 | 2 | 0.070 |
Why?
|
| Exons | 2 | 2016 | 97 | 0.070 |
Why?
|
| Genetic Markers | 2 | 2016 | 60 | 0.070 |
Why?
|
| Mastectomy, Radical | 1 | 2004 | 1 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2005 | 21 | 0.060 |
Why?
|
| Amnion | 1 | 2004 | 1 | 0.060 |
Why?
|
| Crown-Rump Length | 1 | 2004 | 1 | 0.060 |
Why?
|
| Pregnancy Reduction, Multifetal | 1 | 2004 | 1 | 0.060 |
Why?
|
| Sex Characteristics | 1 | 2004 | 9 | 0.060 |
Why?
|
| Cell Survival | 2 | 2015 | 45 | 0.060 |
Why?
|
| Chromatography, Liquid | 2 | 2015 | 14 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2004 | 4 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2014 | 5 | 0.060 |
Why?
|
| Transcription Factor RelA | 2 | 2015 | 6 | 0.060 |
Why?
|
| Women's Health | 2 | 2013 | 2 | 0.060 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2023 | 4 | 0.060 |
Why?
|
| Thinness | 1 | 2023 | 1 | 0.060 |
Why?
|
| Overweight | 1 | 2023 | 4 | 0.060 |
Why?
|
| Denosumab | 1 | 2023 | 2 | 0.060 |
Why?
|
| Drug Carriers | 1 | 2003 | 1 | 0.060 |
Why?
|
| Chorionic Gonadotropin | 1 | 2003 | 1 | 0.060 |
Why?
|
| Progesterone Congeners | 2 | 2013 | 2 | 0.060 |
Why?
|
| Electrosurgery | 1 | 2022 | 2 | 0.060 |
Why?
|
| Statistics, Nonparametric | 2 | 2013 | 14 | 0.060 |
Why?
|
| Colposcopy | 1 | 2022 | 1 | 0.060 |
Why?
|
| Conization | 1 | 2022 | 1 | 0.060 |
Why?
|
| Obesity | 1 | 2023 | 86 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2014 | 12 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2016 | 26 | 0.050 |
Why?
|
| Morals | 1 | 2022 | 1 | 0.050 |
Why?
|
| Oocyte Donation | 1 | 2022 | 1 | 0.050 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2022 | 3 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2015 | 19 | 0.050 |
Why?
|
| Bridged-Ring Compounds | 1 | 2022 | 1 | 0.050 |
Why?
|
| Brain | 1 | 2023 | 153 | 0.050 |
Why?
|
| Aminopyridines | 1 | 2021 | 3 | 0.050 |
Why?
|
| Purines | 1 | 2021 | 4 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2022 | 96 | 0.050 |
Why?
|
| Fear | 1 | 2021 | 3 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2021 | 32 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2022 | 120 | 0.050 |
Why?
|
| Immunity | 1 | 2021 | 18 | 0.050 |
Why?
|
| Dysmenorrhea | 1 | 2021 | 1 | 0.050 |
Why?
|
| Vaccination | 1 | 2021 | 21 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 65 | 0.050 |
Why?
|
| Hyaluronic Acid | 1 | 2021 | 1 | 0.050 |
Why?
|
| Phase Transition | 1 | 2021 | 2 | 0.050 |
Why?
|
| Temperature | 1 | 2021 | 29 | 0.050 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2021 | 1 | 0.050 |
Why?
|
| Human papillomavirus 16 | 1 | 2021 | 2 | 0.050 |
Why?
|
| Human papillomavirus 18 | 1 | 2021 | 3 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 10 | 0.050 |
Why?
|
| Midwifery | 1 | 2021 | 1 | 0.050 |
Why?
|
| Nurse Midwives | 1 | 2021 | 1 | 0.050 |
Why?
|
| Sampling Studies | 2 | 2015 | 2 | 0.050 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2020 | 1 | 0.050 |
Why?
|
| Base Sequence | 2 | 2016 | 275 | 0.050 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 1 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2020 | 4 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2020 | 5 | 0.050 |
Why?
|
| Personality Inventory | 1 | 2020 | 1 | 0.050 |
Why?
|
| Cell Death | 2 | 2011 | 20 | 0.050 |
Why?
|
| Neuroticism | 1 | 2020 | 3 | 0.050 |
Why?
|
| Mental Health | 1 | 2020 | 4 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 29 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 417 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2020 | 59 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2020 | 17 | 0.050 |
Why?
|
| Plasma Cells | 1 | 2020 | 9 | 0.050 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 25 | 0.050 |
Why?
|
| Embryology | 1 | 2020 | 1 | 0.050 |
Why?
|
| Disease | 1 | 2020 | 6 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2020 | 37 | 0.050 |
Why?
|
| Cell Shape | 1 | 2020 | 4 | 0.050 |
Why?
|
| Mutation Rate | 1 | 2020 | 16 | 0.050 |
Why?
|
| Glycolysis | 1 | 2020 | 11 | 0.050 |
Why?
|
| RNA, Long Noncoding | 1 | 2020 | 36 | 0.050 |
Why?
|
| Homeostasis | 1 | 2020 | 50 | 0.050 |
Why?
|
| Radiodermatitis | 1 | 2020 | 1 | 0.050 |
Why?
|
| Radiometry | 1 | 2020 | 1 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2020 | 1 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2020 | 3 | 0.050 |
Why?
|
| Myalgia | 1 | 2020 | 1 | 0.050 |
Why?
|
| Epigenomics | 1 | 2020 | 24 | 0.050 |
Why?
|
| Databases, Genetic | 1 | 2020 | 62 | 0.050 |
Why?
|
| Organoplatinum Compounds | 1 | 2019 | 1 | 0.050 |
Why?
|
| Apgar Score | 2 | 2012 | 2 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2020 | 47 | 0.050 |
Why?
|
| Oncogenes | 1 | 2019 | 3 | 0.050 |
Why?
|
| Platinum Compounds | 2 | 2011 | 2 | 0.050 |
Why?
|
| Multigene Family | 1 | 2019 | 30 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 138 | 0.040 |
Why?
|
| Particle Size | 1 | 2019 | 4 | 0.040 |
Why?
|
| Patient Dropouts | 1 | 2019 | 1 | 0.040 |
Why?
|
| Tissue Culture Techniques | 1 | 2019 | 5 | 0.040 |
Why?
|
| Subcellular Fractions | 1 | 2019 | 8 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 2019 | 3 | 0.040 |
Why?
|
| Nanostructures | 1 | 2019 | 3 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2019 | 2 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2019 | 2 | 0.040 |
Why?
|
| Lymphatic Irradiation | 1 | 2019 | 1 | 0.040 |
Why?
|
| Mammaplasty | 1 | 2019 | 3 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2019 | 4 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2019 | 2 | 0.040 |
Why?
|
| Pain Management | 1 | 2019 | 2 | 0.040 |
Why?
|
| Hydroxychloroquine | 1 | 2019 | 1 | 0.040 |
Why?
|
| Pregnancy, Twin | 1 | 2019 | 2 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2019 | 4 | 0.040 |
Why?
|
| Azathioprine | 1 | 2019 | 2 | 0.040 |
Why?
|
| Pain | 1 | 2019 | 9 | 0.040 |
Why?
|
| Microfluidics | 1 | 2019 | 1 | 0.040 |
Why?
|
| International Agencies | 1 | 2018 | 1 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2018 | 2 | 0.040 |
Why?
|
| Consensus | 1 | 2018 | 5 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 22 | 0.040 |
Why?
|
| Age of Onset | 1 | 2019 | 40 | 0.040 |
Why?
|
| Mitochondria | 1 | 2020 | 150 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 6 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2018 | 1 | 0.040 |
Why?
|
| Formaldehyde | 1 | 2018 | 2 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2018 | 16 | 0.040 |
Why?
|
| Cardiotoxicity | 1 | 2018 | 8 | 0.040 |
Why?
|
| DNA Damage | 1 | 2019 | 77 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 173 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 70 | 0.040 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1998 | 13 | 0.040 |
Why?
|
| Filgrastim | 1 | 2017 | 1 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2017 | 5 | 0.040 |
Why?
|
| Leukemia | 1 | 1998 | 37 | 0.040 |
Why?
|
| Embryo Transfer | 1 | 2017 | 3 | 0.040 |
Why?
|
| Counseling | 1 | 2017 | 3 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2017 | 5 | 0.040 |
Why?
|
| Methotrexate | 1 | 1997 | 4 | 0.040 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2017 | 1 | 0.040 |
Why?
|
| Decidua | 1 | 2017 | 1 | 0.040 |
Why?
|
| Cell Communication | 1 | 2017 | 11 | 0.040 |
Why?
|
| Cadherins | 1 | 2017 | 7 | 0.040 |
Why?
|
| Inguinal Canal | 1 | 2016 | 2 | 0.040 |
Why?
|
| Health Facility Size | 1 | 2016 | 1 | 0.040 |
Why?
|
| Prenatal Diagnosis | 1 | 2016 | 7 | 0.040 |
Why?
|
| Propensity Score | 1 | 2016 | 1 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 10 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2017 | 48 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 4 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 3 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2016 | 2 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 8 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 102 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2015 | 12 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 14 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2015 | 13 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2015 | 1 | 0.030 |
Why?
|
| Workload | 1 | 2015 | 1 | 0.030 |
Why?
|
| Receptors, Virus | 1 | 2015 | 3 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2015 | 12 | 0.030 |
Why?
|
| Gestational Age | 2 | 2006 | 4 | 0.030 |
Why?
|
| Fatal Outcome | 2 | 2006 | 16 | 0.030 |
Why?
|
| Synaptophysin | 1 | 2015 | 1 | 0.030 |
Why?
|
| Chromogranin A | 1 | 2015 | 1 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2015 | 10 | 0.030 |
Why?
|
| I-kappa B Kinase | 1 | 2015 | 2 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2015 | 3 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2015 | 4 | 0.030 |
Why?
|
| Caspase 9 | 1 | 2015 | 2 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2015 | 5 | 0.030 |
Why?
|
| Caspase 8 | 1 | 2015 | 5 | 0.030 |
Why?
|
| Antibodies | 1 | 2015 | 11 | 0.030 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2015 | 6 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 64 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2015 | 11 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2015 | 3 | 0.030 |
Why?
|
| Algorithms | 1 | 2016 | 165 | 0.030 |
Why?
|
| Protein Binding | 1 | 2015 | 97 | 0.030 |
Why?
|
| Phycocyanin | 1 | 2014 | 1 | 0.030 |
Why?
|
| Phycoerythrin | 1 | 2014 | 1 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 2014 | 5 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2014 | 9 | 0.030 |
Why?
|
| Estriol | 1 | 2014 | 1 | 0.030 |
Why?
|
| Estrone | 1 | 2014 | 1 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 186 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2015 | 83 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 301 | 0.030 |
Why?
|
| Laboratories | 1 | 2014 | 1 | 0.030 |
Why?
|
| International Cooperation | 1 | 2014 | 7 | 0.030 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2014 | 1 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2014 | 2 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 79 | 0.030 |
Why?
|
| Medical Illustration | 1 | 2014 | 1 | 0.030 |
Why?
|
| Colpotomy | 1 | 2014 | 1 | 0.030 |
Why?
|
| Photography | 1 | 2014 | 4 | 0.030 |
Why?
|
| Clinical Chemistry Tests | 1 | 2013 | 1 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 1 | 0.030 |
Why?
|
| Formazans | 1 | 2013 | 1 | 0.030 |
Why?
|
| Tetrazolium Salts | 1 | 2013 | 1 | 0.030 |
Why?
|
| Receptor Cross-Talk | 1 | 2013 | 1 | 0.030 |
Why?
|
| Caspases | 1 | 2013 | 2 | 0.030 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 17 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2013 | 15 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2013 | 31 | 0.030 |
Why?
|
| Chemokines | 1 | 2013 | 12 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2013 | 1 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2013 | 20 | 0.030 |
Why?
|
| Flucytosine | 1 | 2013 | 1 | 0.030 |
Why?
|
| Measles Vaccine | 1 | 2013 | 1 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2013 | 6 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 3 | 0.030 |
Why?
|
| Belgium | 1 | 2013 | 5 | 0.030 |
Why?
|
| Reference Values | 1 | 2013 | 11 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2013 | 5 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 122 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 2013 | 1 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2013 | 43 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2012 | 2 | 0.030 |
Why?
|
| Cholinesterases | 1 | 2012 | 1 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 2012 | 3 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 21 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 15 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 14 | 0.030 |
Why?
|
| Clone Cells | 1 | 2012 | 20 | 0.030 |
Why?
|
| Organ Preservation | 1 | 2012 | 1 | 0.030 |
Why?
|
| Carcinoma, Ductal | 1 | 2012 | 1 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2012 | 40 | 0.030 |
Why?
|
| Steroids | 1 | 2012 | 2 | 0.030 |
Why?
|
| Focal Adhesions | 1 | 2012 | 3 | 0.030 |
Why?
|
| Phospholipase D | 1 | 2012 | 4 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2011 | 1 | 0.030 |
Why?
|
| Angiopoietins | 1 | 2011 | 1 | 0.030 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2011 | 1 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 210 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2011 | 7 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2011 | 15 | 0.030 |
Why?
|
| Indazoles | 1 | 2011 | 1 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2011 | 43 | 0.030 |
Why?
|
| Infusions, Parenteral | 1 | 2011 | 1 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 9 | 0.030 |
Why?
|
| Cell Division | 1 | 2011 | 22 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2011 | 1 | 0.030 |
Why?
|
| Menstruation | 1 | 2011 | 1 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2011 | 1 | 0.030 |
Why?
|
| Infant, Low Birth Weight | 1 | 2011 | 2 | 0.030 |
Why?
|
| Stillbirth | 1 | 2011 | 3 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2011 | 1 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2011 | 1 | 0.030 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 5 | 0.030 |
Why?
|
| Demography | 1 | 2011 | 5 | 0.020 |
Why?
|
| Nanog Homeobox Protein | 1 | 2011 | 2 | 0.020 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2011 | 2 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 1 | 0.020 |
Why?
|
| Trust | 1 | 2010 | 1 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2010 | 1 | 0.020 |
Why?
|
| Mammography | 1 | 2010 | 1 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2010 | 2 | 0.020 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2010 | 2 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 18 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2010 | 1 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 6 | 0.020 |
Why?
|
| Salpingectomy | 1 | 2009 | 1 | 0.020 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2009 | 3 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2009 | 16 | 0.020 |
Why?
|
| Endoscopy | 1 | 2009 | 2 | 0.020 |
Why?
|
| Phosphoserine | 1 | 2008 | 2 | 0.020 |
Why?
|
| Wound Healing | 1 | 2008 | 9 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2008 | 21 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 45 | 0.020 |
Why?
|
| Mammary Glands, Animal | 1 | 2008 | 1 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 21 | 0.020 |
Why?
|
| Guanosine | 1 | 2007 | 1 | 0.020 |
Why?
|
| Uridine | 1 | 2007 | 2 | 0.020 |
Why?
|
| Ions | 1 | 2007 | 10 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2007 | 13 | 0.020 |
Why?
|
| Siblings | 1 | 2008 | 28 | 0.020 |
Why?
|
| Adenosine | 1 | 2007 | 8 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2008 | 60 | 0.020 |
Why?
|
| Arteriovenous Malformations | 1 | 2007 | 1 | 0.020 |
Why?
|
| Placenta Diseases | 1 | 2007 | 1 | 0.020 |
Why?
|
| Sacrum | 1 | 2007 | 2 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 20 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2008 | 60 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 111 | 0.020 |
Why?
|
| Gels | 1 | 2006 | 1 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2006 | 1 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2006 | 1 | 0.020 |
Why?
|
| Silicone Elastomers | 1 | 2006 | 2 | 0.020 |
Why?
|
| Turkeys | 1 | 2006 | 2 | 0.020 |
Why?
|
| Needles | 1 | 2006 | 2 | 0.020 |
Why?
|
| Vacuum | 1 | 2006 | 2 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2006 | 3 | 0.020 |
Why?
|
| Fetal Monitoring | 1 | 2006 | 1 | 0.020 |
Why?
|
| Parity | 1 | 2006 | 1 | 0.020 |
Why?
|
| Suburban Population | 1 | 2006 | 1 | 0.020 |
Why?
|
| Maternal Age | 1 | 2006 | 5 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 2006 | 2 | 0.020 |
Why?
|
| Cell Extracts | 1 | 2006 | 6 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2006 | 14 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2006 | 21 | 0.020 |
Why?
|
| Ovarian Cysts | 1 | 2006 | 1 | 0.020 |
Why?
|
| Calcinosis | 1 | 2006 | 6 | 0.020 |
Why?
|
| Brain Diseases | 1 | 2006 | 15 | 0.020 |
Why?
|
| Limb Deformities, Congenital | 1 | 2006 | 18 | 0.020 |
Why?
|
| Oligohydramnios | 1 | 2004 | 1 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2004 | 1 | 0.020 |
Why?
|
| Twins | 1 | 2004 | 2 | 0.020 |
Why?
|
| Sex Factors | 1 | 2004 | 35 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2004 | 146 | 0.010 |
Why?
|
| Albumins | 1 | 2003 | 1 | 0.010 |
Why?
|
| Ligands | 1 | 2003 | 10 | 0.010 |
Why?
|
